Loading company…
PsiThera develops oral small molecules for immunological and inflammatory diseases.
Founded in 2022 and based in Watertown, US, PsiThera develops oral therapies for immunology and inflammatory diseases. Its QUAISAR platform models protein motion to identify potential drug targets, including in the TNF superfamily. The company raised USD 47.50 mn in Series A funding from Eurofarma Ventures and Lightstone Ventures.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in